CS
ONCT

Credit Suisse’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Credit Suisse’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4411
2022
Q2 		$0 Buy
+1
New +$22 ﹤0.01% 4467
2014
Q3 		– Sell
-26
Closed -$51K – 4696
2014
Q2 		$51K Buy
26
+11
+73% +$21.8K ﹤0.01% 4591
2014
Q1 		$32K Sell
15
-2
-12% -$4.98K ﹤0.01% 4603
2013
Q4 		$39K Sell
17
-55
-76% -$126K ﹤0.01% 4543
2013
Q3 		$205K Buy
72
+45
+167% +$224K ﹤0.01% 3954
2013
Q2 		$246K Buy
+27
New +$208K ﹤0.01% 3751

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credit Suisse's ONCT Position: Q3 2022 in Review

Credit Suisse sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in ONCT in Q2 2013 and held it in 6 quarters. The position peaked at $246K in Q2 2013. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Credit Suisse reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Oncternal Therapeutics, Inc. Common Stock share in Q3 2022.
  • Credit Suisse first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • Credit Suisse's Oncternal Therapeutics, Inc. Common Stock position peaked at $246K in Q2 2013.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.